Nivestim (Filgrastim)
filgrastim 300 microgram/0.5 mL injection, 10 x 0.5 mL syringes · INJECTION · PBS code 6291D
STREAMLINEDWhat it costs
AU$58.73 PBS-determined price per 20 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2019-10-01.
- • Repeats: 11.
- • PBS program: HS.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Chemotherapy-induced neutropenia
Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND
Patient must be at greater than 20% risk of developing febrile neutropenia; or
Patient must be at substantial risk (greater than 20%) of prolonged severe neutropenia for more than or equal to seven days.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Chemotherapy-induced neutropenia
Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND
Patient must have had a prior episode of febrile neutropenia; or
Patient must have had a prior episode of prolonged severe neutropenia for more than or equal to seven days.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Mobilisation of peripheral blood progenitor cells
The treatment must be to facilitate harvest of peripheral blood progenitor cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Mobilisation of peripheral blood progenitor cells
The treatment must be in a normal volunteer for use in allogeneic transplantation.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Assisting bone marrow transplantation
Patient must be receiving marrow-ablative chemotherapy prior to the transplantation.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Assisting autologous peripheral blood progenitor cell transplantation
The treatment must be following marrow-ablative chemotherapy for non-myeloid malignancy prior to the transplantation.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe congenital neutropenia
Patient must have an absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart; AND
Patient must have had a bone marrow examination that has shown evidence of maturational arrest of the neutrophil lineage.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe chronic neutropenia
Patient must have an absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart; or
Patient must have neutrophil dysfunction; AND
Patient must have experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months; or
Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Chronic cyclical neutropenia
Patient must have an absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles; AND
Patient must have experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics; or
Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months.
Sponsor: Pfizer Australia Pty Ltd ABN 50 008 422 348
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.